Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review.

ABSTRACT:

Background

Platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) are currently regarded as the standard treatment modalities for advanced non-small cell lung cancer (NSCLC) characterized by EGFR exon 20 insertion (ex20ins) mutations; however, their efficacy is suboptimal. Recent developments in targeted therapies, including agents such as amivantamab, mobocertinib, and sunvozertinib, have shown promise in patients with pretreated ex20ins-positive NSCLC. However, a comprehensive systematic review assessing the efficacy and safety of these later-line Targeted therapies has not yet been conducted.

Methods

A systematic search for studies pertaining to later-line treatment options for patients with ex20ins mutations was conducted using PubMed, Embase, and the Cochra

SUBMITTER: Wen Q 

PROVIDER: S-EPMC12757754 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature